Sale

Urinary Incontinence Drugs Market

Urinary Incontinence Drugs Market Size, Share, Forecast: By Incontinence Type: Urge Incontinence, Overflow Incontinence, Stress Incontinence, Mixed Incontinence, Other Type; By Drug Type: Anticholinergic, Skeletal Muscle Relaxants, Antidepressants, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Urinary Incontinence Drugs Market Outlook

The urinary incontinence drugs market size was valued at USD 12028.45 million in 2023, driven by the increasing geriatric population across the 7 major markets. The market size is anticipated to grow at a CAGR of 7% during the forecast period of 2024-2032 to achieve a value of USD 22199 million by 2032.

 

Urinary Incontinence Drugs: Introduction

Urinary incontinence is a medical condition in which the patient suffers from unintentional passing of urine. It is a common problem affecting millions of people around the world. There are several types of urinary incontinence, including stress incontinence – when urine leaks out at times when the patient’s bladder is under pressure; for example, when they cough or laugh.

 

Urinary Incontinence Drugs Market Analysis

The urinary incontinence drugs market is witnessing significant developments that are expected to influence market growth positively. For example, Versameb's VMB-100, an investigational drug encoding human insulin-like growth factor-1 (IGF-1), has received FDA acceptance for an investigational new drug (IND) application. This marks a significant step toward addressing stress urinary incontinence (SUI) exclusively in female patients. The initiation of a phase 2A open-label dose ascending study in the first half of 2024 aims to evaluate VMB-100's safety, tolerability, and efficacy in treating moderate SUI.

 

Additionally, a potential breakthrough in the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) has emerged with the investigational gene therapy URO-902. Results from a phase 2A trial indicate that single-dose URO-902, administered at 24 mg and 48 mg, exhibited clinically relevant reductions in daily micturitions, urgency episodes, and UUI episodes compared to a placebo. This promising data suggests a novel and effective treatment strategy for women facing these conditions, further expected to support the urinary incontinence drugs market growth.

 

Furthermore, Alembic Pharmaceuticals has received final approval from the FDA for Fesoterodine Fumarate Extended-Release tablets, designed to treat overactive bladder in adults. The approval positions this medication as therapeutically equivalent to the reference listed drug product Toviaz Extended-Release Tablets by Pfizer Inc. This milestone enhances the available options for managing overactive bladder and contributes to the overall growth of the urinary incontinence drugs market. The collective impact of these developments, encompassing innovative therapies and expanded treatment options, is expected to drive market growth by meeting the evolving needs of patients and offering more effective solutions for urinary incontinence.

 

Urinary Incontinence Drugs Market Segmentations

Market Breakup by Incontinence Type

  • Urge Incontinence
  • Overflow Incontinence
  • Stress Incontinence
  • Mixed Incontinence
  • Other Type

 

Market Breakup by Drug Type

  • Anticholinergic
  • Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others

 

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online pharmacies

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

 

Urinary Incontinence Drugs Market Overview

The market for urinary incontinence treatment drugs is poised for substantial growth, primarily driven by the rising prevalence of urinary incontinence, a condition that is expected to escalate the demand for effective treatment drugs. The increasing geriatric population worldwide is a contributing factor to the growth of the market.

 

As regulatory bodies continue to grant approvals for new drugs in this category, it is further expected to propel the urinary incontinence drugs market growth. This positive trend can be significantly exhibited by the situation in North America, where the urinary incontinence treatment drugs market is anticipated to witness significant expansion in the near future. Factors contributing to this growth include the high prevalence of orthopedic disorders and dysfunctions, favorable health reimbursement policies, and an increased level of awareness.

 

Moreover, the increasing incidence of neurological disorders in the region adds another dimension to the market's expansion, boosting the demand for urinary incontinence treatment drugs. With these drivers contributing to the market, the urinary incontinence drugs market is expected to experience sustained growth, meeting the healthcare needs of an expanding patient population and driving innovation in the field.

 

Urinary Incontinence Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Johnson & Johnson
  • Pfizer
  • Astellas Pharma
  • Allergan
  • Takeda Pharmaceuticals Company
  • Merck KGaA.
  • Sanofi S.A.
  • Kissei Pharmaceutical
  • Kyorin Holding
  • Urovant Sciences
  • Cook MyoSite
  • elicept Therapeutics
  • Astellas Pharma

 

Please note that this list only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Incontinence Type
  • Drug Type
  • Distribution Channel
  • Region
Breakup by Incontinence Type
  • Urge Incontinence
  • Overflow Incontinence
  • Stress Incontinence
  • Mixed Incontinence
  • Other Type
Breakup by Drug Type
  • Anticholinergic
  •  Skeletal Muscle Relaxants
  • Antidepressants
  • Alpha Blockers
  • Topical Estrogens
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online pharmacies
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Johnson & Johnson
  • Pfizer Inc
  • Astellas Pharma
  • Allergan
  • Takeda Pharmaceuticals Company
  • Merck KGaA.
  • Sanofi S.A.
  • Kissei Pharmaceutical
  • Kyorin holding
  • Urovant Sciences
  • Cook MyoSite
  • elicept Therapeutics
  • Astellas Pharma

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3     Urinary Incontinence Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Urinary Incontinence Drugs Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Treatment Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Treatment Success Rate
7    Urinary Incontinence Drugs Epidemiology Analysis – 7MM
    7.1    7MM Epidemiology Scenario Overview (2017-2032)
    7.2    United States Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
    7.3    EU-4 and United Kingdom Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
        7.3.1    Germany Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
        7.3.2    France Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
        7.3.3    Italy Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
        7.3.4    Spain Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
        7.3.5    United Kingdom Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
    7.4    Japan Urinary Incontinence Drugs Epidemiology  Forecast (2017-2032)
8    Urinary Incontinence Drugs Market Overview – 7MM
    8.1    Urinary Incontinence Drugs Market Historical Value (2017-2023) 
    8.2    Urinary Incontinence Drugs Market Forecast Value (2024-2032)
9    Urinary Incontinence Drugs Market Landscape – 7MM
    9.1    Urinary Incontinence Drugs Developers Landscape
        9.1.1    Analysis by Year of Establishment
        9.1.2    Analysis by Company Size
        9.1.3    Analysis by Region
    9.2    Urinary Incontinence Drugs Product Landscape
        9.2.1    Analysis by Products
        9.2.2    Analysis by Indications
        9.2.3    Analysis by Route of Administration
10    Urinary Incontinence Drugs Challenges and Unmet Needs
    10.1    Treatment Pathway Challenges
    10.2    Compliance and Drop-Out Analysis
    10.3    Awareness and Prevention Gaps
11    Cost of Treatment
12    Urinary Incontinence Drugs Market Dynamics

    12.1    Market Drivers and Constraints
    12.2    SWOT Analysis
    12.3    Porter’s Five Forces Model
    12.4    Key Demand Indicators 
    12.5    Key Price Indicators
    12.6    Industry Events, Initiatives, and Trends  
    12.7    Value Chain Analysis
13    Urinary Incontinence Drugs Market Segmentation – 7MM
    13.1     Urinary Incontinence Drugs Market by Incontinence Type
        13.1.1    Market Overview
        13.1.2    Urge Incontinence
        13.1.3    Overflow Incontinence
        13.1.4    Stress Incontinence
        13.1.5    Mixed Incontinence
        13.1.6    Other Type
    13.2     Urinary Incontinence Drugs Market by Drug Type
        13.2.1    Market Overview
        13.2.2    Anticholinergic
        13.2.3    Skeletal Muscle Relaxants
        13.2.4    Antidepressants
        13.2.5    Alpha Blockers
        13.2.6    Topical Estrogens
        13.2.7    Others
    13.3     Urinary Incontinence Drugs Market by Distribution Channel
        13.3.1    Market Overview
        13.3.2    Hospital Pharmacies
        13.3.3    Retail Pharmacies
        13.3.4    Online pharmacies
    13.4    Urinary Incontinence Drugs Market by Region
        13.4.1    Market Overview
        13.4.2    United States
        13.4.3    EU-4 and the United Kingdom
            13.4.3.1    Germany
            13.4.3.2    France
            13.4.3.3    Italy
            13.4.3.4    Spain
            13.4.3.5    United Kingdom    
        13.4.4    Japan
14    United States Urinary Incontinence Drugs Market
    14.1    Urinary Incontinence Drugs Market Historical Value (2017-2023) 
    14.2    Urinary Incontinence Drugs Market Forecast Value (2024-2032)
    14.3    Urinary Incontinence Drugs Market by Disease Type
    14.4    Urinary Incontinence Drugs Market by Treatment Type
15    EU-4 and United Kingdom Urinary Incontinence Drugs Market
    15.1    Urinary Incontinence Drugs Market Historical Value (2017-2023) 
    15.2    Urinary Incontinence Drugs Market Forecast Value (2024-2032)
    15.3    Germany Urinary Incontinence Drugs Market Overview
        15.3.1    Urinary Incontinence Drugs Market by Disease Type
        15.3.2    Urinary Incontinence Drugs Market by Treatment Type
    15.4    France Urinary Incontinence Drugs Market Overview
        15.4.1    Urinary Incontinence Drugs Market by Disease Type
        15.4.2    Urinary Incontinence Drugs Market by Treatment Type
    15.5    Italy Urinary Incontinence Drugs Market Overview
        15.5.1    Urinary Incontinence Drugs Market by Disease Type
        15.5.2    Urinary Incontinence Drugs Market by Treatment Type
    15.6    Spain Urinary Incontinence Drugs Market Overview
        15.6.1    Urinary Incontinence Drugs Market by Disease Type
        15.6.2    Urinary Incontinence Drugs Market by Treatment Type
    15.7    United Kingdom Urinary Incontinence Drugs Market Overview
        15.7.1    Urinary Incontinence Drugs Market by Disease Type
        15.7.2    Urinary Incontinence Drugs Market by Treatment Type
16    Japan Urinary Incontinence Drugs Market
    16.1    Urinary Incontinence Drugs Market Historical Value (2017-2023) 
    16.2    Urinary Incontinence Drugs Market Forecast Value (2024-2032)
        16.2.1    Urinary Incontinence Drugs Market by Disease Type
        16.2.2    Urinary Incontinence Drugs Market by Treatment Type
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Johnson & Johnson
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisition
        22.1.5    Certifications
    22.2    Pfizer Inc
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisition
        22.2.5    Certifications
    22.3    Astellas Pharma
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisition
        22.3.5    Certifications
    22.4    Allergan
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisition
        22.4.5    Certifications
    22.5    Takeda Pharmaceuticals Company
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisition
        22.5.5    Certifications
    22.6    Merck KGaA.
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisition
        22.6.5    Certifications
    22.7    Sanofi S.A.
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisition
        22.7.5    Certifications
    22.8    Kissei Pharmaceutical
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisition
        22.8.5    Certifications
    22.9    Kyorin holding
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisition
        22.9.5    Certifications
    22.10    Urovant Sciences
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisition
        22.10.5    Certifications
    22.11    Cook MyoSite
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisition
        22.11.5    Certifications
    22.12    elicept Therapeutics
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisition
        22.12.5    Certifications
    22.13    Astellas Pharma
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisition
        22.13.5    Certifications
23     Urinary Incontinence Drugs Market - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)

    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 12028.45 million in 2023, driven by the increased geriatric patients.

The market is anticipated to grow at a CAGR of 7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 22199 million by 2032.

The rising prevalence of urinary incontinence, coupled with the growing geriatric population, are among the major factors driving the market growth.

The market is driven by continuous drug approvals and research and development for their clinical trials.

The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. 

There are various types of incontinence such as urge incontinence, overflow incontinence, stress incontinence, and mixed incontinence, among other type.

Drugs like anticholinergic, skeletal muscle relaxants, antidepressants, alpha-blockers, and topical estrogens, among others are used to treat this condition.

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

Key players involved in the market are Johnson & Johnson, Pfizer Inc, Astellas Pharma, Allergan, Takeda Pharmaceuticals Company, Merck KGaA., Sanofi S.A., Kissei Pharmaceutical, Kyorin Holding, Urovant Sciences, Cook MyoSite, elicept Therapeutics, and Astellas Pharma.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER